Activity Overview
This educational activity is an archive of the live presentation
held on May 31, 2026.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This
educational activity is directed toward medical oncologists, thoracic surgeons,
pulmonologists, radiation oncologists, pathologists, nurse practitioners,
physician assistants, pharmacists, oncology nurses, and other health care
providers who manage patients with early-stage non-small cell lung cancer (NSCLC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the role of key actionable biomarkers and current molecular testing strategies in advanced NSCLC
- Evaluate recent clinical trial data on approved and emerging targeted therapies and immunotherapies for advanced NSCLC
- Apply molecular profiling results and clinical characteristics to develop individualized treatment plans for patients with advanced NSCLC
Enriqueta Felip, MD, PhD
Professor
of Medicine
Universitat
Autònoma de Barcelona
Section
Chief, Medical Oncology Department
Director,
Thoracic Oncology Unit
Vall
d’Hebron University Hospital
Vall
d’Hebron Institute of Oncology
Barcelona,
Spain
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Ellipses Pharma, Genentech/Roche, Gilead, GSK, iTeos, Janssen/Johnson & Johnson, Lilly, Medical Trends, Medscape, Moderna, MSD, Pfizer, PeerVoice, PharmaMar, Pierre Fabre, Regeneron, Seagen, Tubulis GmbH
Justin Gainor, MD
Associate
Professor of Medicine, Harvard Medical School
Program
Director, Center for Thoracic Cancers
Director,
Targeted Immunotherapy
Massachusetts
General Hospital
Dana-Farber
Cancer Institute
Boston,
MA
Disclosures: Advisor, Consultant, Fee for Service Recipient: AI Proteins, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Ellipses Pharma, Genentech/Roche, Jazz Pharmaceuticals, Johnson & Johnson, Marina Oncology (Curie), Merck, Novartis, Nuvalent, Pfizer, Revolution Medicine, Rigel, Sanofi, Summit, Tempus; Grant/Research Funding: Moderna, Novartis
Julia Rotow, MD
Assistant
Professor
Harvard
Medical School
Clinical
Director, Lowe Center for Thoracic Oncology
Dana-Farber
Cancer Institute
Boston,
MA
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Amgen, AstraZeneca, BioAtla, BlossomHill, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, G1 Therapeutics, Genentech, Gilead, Guardant Health, Jazz Pharmaceuticals, Johnson & Johnson, Merus, Novocure, Nuvalent, Nuvation Bio, Pfizer, Regeneron, Sanofi-Genzyme, Summit Therapeutics, Takeda; Grant/Research Funding: AbbVie, Altor Bioscience, AstraZeneca, Bicycle Therapeutics, BioAtla, Black Diamond, BlossomHill, Blueprint Medicines, Bristol Myers Squibb, Duality, Enliven Therapeutics, EpimAb, ImmunityBio, Loxo Oncology, ORIC Pharmaceuticals, RedCloud Bio, Summit, Synthekine, Regeneron
Urs Weber, MD
Assistant
Professor, Thoracic Oncology
Division
of Medical Oncology
University
of Colorado Anschutz Medical Campus
Aurora,
CO
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Janssen Biotech
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
